On January 17, 2023 Glycotope GmbH, a biotechnology company with a proprietary platform technology for developing antibodies against proteins carrying tumor-specific carbohydrate structures, repoerted that it will present its glyco-engineered cell lines at GlycoBioTec 2023 – 3rd International GlycoBioTec Symposium, being held in Berlin, Germany, on 17 and 18 January 2023 (Press release, Glycotope, JAN 17, 2023, View Source [SID1234626294]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: "Our glyco-engineered cell lines provide the basis for the generation of therapeutic antibodies with increased tumor specificity and safety for highly potent therapeutic approaches like ADCs, CARs and radiotherapeutics. It represents a versatile tool for target validation and screening of glycosylation-dependent protein binding antibodies. It is great, that our scientists have the opportunity to present their work at GlycoBioTec 2023 and to discuss with other glycobiotechnology experts."

Poster details are as follows:

Abstract: Download here

Title: Using glyco-engineered cells with flexible expression of tumor-associated carbohydrates for the generation of highly tumor-specific antibodies

Poster Presentation: 17 January 2023, 6:00am – 7:00pm CET

Contact Information:

Glycotope GmbH

Dr. Patrik Kehler (CSO)

Phone: +49 30 9489 2600

Email: [email protected]